Phase I study of pemetrexed with sorafenib in advanced solid tumors

Purpose

To determine if combination treatment with pemetrexed and sorafenib is safe and tolerable in patients with advanced solid tumors.

Results

Thirty-seven patients were enrolled and 36 patients were treated (24 in cohort A; 12 in cohort B). The cohort A dose schedule resulted in problematic cumulative toxicity, while the cohort B dose schedule was found to be more tolerable. The maximum tolerated dose (MTD) was pemetrexed 750 mg/m² every 14 days with oral sorafenib 400 mg given twice daily on days 1–5. Because dosing delays and modifications were associated with the MTD, the recommended phase II dose was declared to be pemetrexed 500 mg/m² every 14 days with oral sorafenib 400 mg given twice daily on days 1–5. Thirty-three patients were evaluated for antitumor activity. One complete response and 4 partial responses were observed (15% overall response rate). Stable disease was seen in 15 patients (45%). Four patients had a continued response at 6 months, including 2 of 5 patients with triple-negative breast cancer.

Experimental Design

A phase I trial employing a standard 3 + 3 design was conducted in patients with advanced solid tumors. Cohort A involved a novel dose escalation schema exploring doses of pemetrexed every 14 days with continuous sorafenib. Cohort B involved a modified schedule of sorafenib dosing on days 1–5 of each 14-day pemetrexed cycle. Radiographic assessments were conducted every 8 weeks.

Conclusions

Pemetrexed and intermittent sorafenib therapy is a safe and tolerable combination for patients, with promising activity seen in patients with breast cancer.

Genetic differentiation between two host "races" and two species of cleptoparasitic bees and between their two hosts

In this paper we test the following two hypotheses: (1) that apparently conspecific samples of the cleptoparasitic bee Coelioxys funeraria, differing markedly in size and reared from different host species, do indeed represent one panmictic population; (2) that bees that nest in holes in wood or twigs have higher levels of genetic variation than those nesting in the ground. Based upon 41 loci, the genetic differences between the two samples of C. funeraria could be explained entirely in terms of sampling error. In contrast, the sympatric C. moesta showed 16 fixed allelic differences from the C. funeraria samples. Similarly, the two hosts of C. funeraria, Megachile relativa and M. inermis, had 21 fixed allelic differences between them out of 42 presumptive gene loci. Heterozygosities among the wood-nesting bees were not particularly high for Hymenoptera, ranging from 0.045 to 0.054. Comparisons of heterozygosity estimates among bees remain ambiguous as to whether soil nesting confers sufficient environmental buffering effects to reduce possible advantages of heterosis in ground-nesting species.

Detoxification Enzyme Differences Between a Herbivorous and Predatory Mite

The detoxification capabilities of the predatory mite Amblyseius fallacis and its herbivorous prey Tetranychus urticae are fundamentally different. The activities of mixed-function oxidase and trans-epoxide hydrolase are higher in the prey than in the predator; those of cis-epoxide hydrolase and glutathione transferase are lower; and esterase activity is similar. Dissimilarities may be related both to differing adaptations to plant allelochemicals and to the higher respiration rate of the predator. Hydrolytic and conjugating reactions appear more important than oxidative pathways in imparting organophosphate resistance to these acarines. These resistances provide insecticide selectivity favorable to the predator and improved integrated pest control.